Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammad Sarwar

Internal Medicine Lake Charles, LA Medical Doctor

NPI 1407823644 CMS profile 335461

1000 Walters St, Lake Charles, LA 70607

Open in the dashboard

General payments

$5,931

126 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammad Sarwar of Lake Charles, LA is reported in the CMS Open Payments database as having received $5,931 across 126 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $581 24
2024 General $2,226 29
2023 General $897 21
2022 General $445 15
2021 General $1,475 21
2020 General $109 7
2019 General $197 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammad Sarwar
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mohammad Sarwar were reported at $581. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mohammad Sarwar Internal Medicine median Middle half National median
2019 $197 $159 $48–$570 $163
2020 $109 $119 $33–$402 $114
2021 $1,475 $135 $37–$521 $132
2022 $445 $141 $42–$496 $149
2023 $897 $149 $45–$519 $160
2024 $2,226 $154 $47–$537 $164
2025 $581 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $3,728 48 payments
  2. Dexcom, Inc. $755 15 payments
  3. Lilly USA, LLC $166 10 payments
  4. Janssen Pharmaceuticals, Inc $142 6 payments
  5. Insulet Corporation $135 3 payments
  6. Merck Sharp & Dohme Corporation $111 1 payment
  7. Astellas Pharma US Inc $105 4 payments
  8. Sanofi-Aventis U.S. LLC $102 5 payments
  9. Novartis Pharmaceuticals Corporation $93 5 payments
  10. Gilead Sciences, Inc. $80 4 payments
  11. Other $513 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,548 112 payments
  2. Travel and Lodging $2,262 12 payments
  3. Education $61 1 payment
  4. Gift $59 1 payment
Products named General payments · program years 2019–2025
  1. MINIMED 780G $2,177 29 payments
  2. InPen $1,339 13 payments
  3. Dexcom G6 Transmitter $640 14 payments
  4. MINIMED 770G $150 3 payments
  5. Omnipod $135 3 payments
  6. DEXCOM G7 GSS (161) $116 1 payment
  7. VERQUVO Cardiovascular $111 1 payment
  8. VERQUVO Cardiovascular $111 1 payment
  9. TZIELD $102 5 payments
  10. XARELTO $85 5 payments
  11. Other $1,156 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 129 drugs

Part D claims

11,471

Median for Internal Medicine: 777

Drug cost

$1,368,788

Median for Internal Medicine: $73,373

Branded share of claims

23%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 195 $250,529
Mounjaro Tirzepatide Brand 104 $141,860
Eliquis Apixaban Brand 120 $137,620
Januvia Sitagliptin Phosphate Brand 72 $103,963
Jardiance Empagliflozin Brand 71 $98,262
Farxiga Dapagliflozin Propanediol Brand 70 $86,654
Trulicity Dulaglutide Brand 39 $75,206
Tradjenta Linagliptin Brand 55 $62,432
Linzess Linaclotide Brand 47 $46,295
Entresto Sacubitril/Valsartan Brand 39 $39,904

The 10 drugs with the highest cost, of 129 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$46,004

Medicare's payments for the services billed

Medicare patients

254

Average age 66

Services billed

826

145 women, 109 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 48%
Diabetes 46%
Arthritis 33%
COPD 26%
Depression 23%
Ischemic heart disease 22%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TZIELD
  • SANOFI-AVENTIS U.S. LLC $41
$41 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $23
$23 — —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

126 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record